https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-12 / Lung Cancer 2010 Nov;70(2):188-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-12 / Lung Cancer 2010 Nov;70(2):188-942010-03-12 00:00:002019-02-15 08:45:35Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-11 / Curr. Opin. Immunol. 2010 Apr;22(2):258-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-11 / Curr. Opin. Immunol. 2010 Apr;22(2):258-632010-03-11 00:00:002019-02-15 08:40:24Building on dendritic cell subsets to improve cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-05 / Cancer Immunol. Immunother. 2010 Oct;59(10):1573-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-05 / Cancer Immunol. Immunother. 2010 Oct;59(10):1573-822010-03-05 00:00:002019-02-15 08:40:24Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-01 / Expert Opin Biol Ther 2010 Mar;10(3):369-79
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-01 / Expert Opin Biol Ther 2010 Mar;10(3):369-792010-03-01 00:00:002019-02-15 08:44:06The evolving role of dendritic cells in cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-28 / Korean J. Physiol. Pharmacol. 2010 Feb;14(1):11-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-28 / Korean J. Physiol. Pharmacol. 2010 Feb;14(1):11-42010-02-28 00:00:002019-02-15 08:47:49Dendritic Cells-based Vaccine and Immune Monitoring for Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-24 / Cell. Immunol. 2010;263(1):9-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-24 / Cell. Immunol. 2010;263(1):9-212010-02-24 00:00:002019-02-15 08:50:11Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-902010-02-18 00:00:002020-09-07 08:01:07Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-09 / Immunol. Cell Biol. 2010 Jul;88(5):596-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-09 / Immunol. Cell Biol. 2010 Jul;88(5):596-6042010-02-09 00:00:002019-02-15 08:44:06Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-662010-02-01 00:00:002019-02-15 08:44:00Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-612010-01-30 00:00:002019-02-15 08:50:36What’s the place of immunotherapy in malignant mesothelioma treatments?
